Evidence map›Paper›PMID 40046016›Full record

ArticleFrontiers in chemistry2025

Therapeutic potential of

Sevgi Altın, Mesut Işık, Cemalettin Alp, Emrah Dikici, Ekrem Köksal, Kevser Kübra Kırboğa, Mithun Rudrapal, Gourav Rakshit, Şükrü Beydemir, Johra Khan

Abstract read
In one paragraph

Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sevgi AltınDepartment of Chemistry, Erzincan Binali Yıldırım University, Faculty of Science and Art, Erzincan, Türkiye.
Mesut IşıkDepartment of Bioengineering, Faculty of Engineering, Bilecik Şeyh Edebali University, Bilecik, Türkiye.
Cemalettin AlpDepartment of Chemistry, Erzincan Binali Yıldırım University, Faculty of Science and Art, Erzincan, Türkiye.
Emrah DikiciScience and Technology Application and Research Center, Aksaray University, Aksaray, Türkiye.
Ekrem KöksalDepartment of Chemistry, Erzincan Binali Yıldırım University, Faculty of Science and Art, Erzincan, Türkiye.
Kevser Kübra KırboğaDepartment of Bioengineering, Faculty of Engineering, Bilecik Şeyh Edebali University, Bilecik, Türkiye.
Mithun RudrapalDepartment of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology and Research, Guntur, India.
Gourav RakshitDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Ranchi, India.
Şükrü BeydemirDepartment of Biochemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Türkiye.
Johra KhanDepartment of Medical Laboratory Sciences, College of Applied Medical Laboratory Sciences, Majmaah University, Al Majma'ah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: LN leaf extracts were prepared via ethanol maceration, followed by filtration and concentration. Phenolic content was analyzed using LC-MS/MS. Antioxidant activity was assessed through ferric thiocyanate, DPPH, ABTS, and FRAP assays. Enzyme inhibition assays targeted AChE, BChE, and α-GLY, with IC50 values from dose-response curves. Results: Vanillic acid and catechin hydrate were the most abundant phenolics. LN extract showed strong lipid peroxidation inhibition (50.53%) compared to Trolox (28.33%) and α-tocopherol (37.79%). Moderate radical scavenging and metal reduction potentials were observed. IC50 values were 2.57 µg/L for AChE, 3.78 µg/L for BChE, and 4.65 µg/L for α-GLY, indicating notable bioactivity. Discussion: LN extracts demonstrated promising antioxidant, antidiabetic, and anticholinergic activities, attributed to high phenolic content. Enzyme inhibition results suggest potential in managing metabolic and neurodegenerative disorders.

Indexed as

antidiabeticantioxidantLaurus nobilis L.molecular dockingmolecular dynamicsphenolic content

Identifiers

PMID40046016
PMCPMC11880275

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.